Brief: Processa Pharma Issues Letter To Shareholders Highlighting Corporate Strategy, Drug Pipeline & Outlook

Processa Pharmaceuticals

29/11/2023 15:59

Nov 29 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS
HIGHLIGHTING CORPORATE STRATEGY, DRUG PIPELINE, AND OUTLOOK
    * PROCESSA PHARMACEUTICALS INC -  NGC-CAPECITABINE PHASE 1B
STUDY
ENROLLMENT IS EXPECTED TO BE COMPLETED BY EARLY 2024
    * PROCESSA PHARMACEUTICALS INC - ASSESSMENT OF SAFETY
PROFILE OF
NGC-CAP IN TOTALITY ACROSS ALL COHORTS IS EXPECTED TO BE
COMPLETED BY MID 2024
    * PROCESSA PHARMACEUTICALS INC -  DISCUSSION WITH FDA TO
DETERMINE
PHASE 2 STUDY DESIGN FOR NGC-CAPECITABINE EXPECTED BY YEAR-END
2023
    * PROCESSA PHARMACEUTICALS INC -  INITIATE SOURCING OF DRUG
SUBSTANCE AND PRODUCT MANUFACTURING SITES FOR NGC-IRINOTECAN
EXPECTED IN 2024
    * PROCESSA PHARMACEUTICALS INC: NGC-GEMCITABINE DISCUSSION
WITH
FDA TO DETERMINE PHASE 2B/3A STUDY DESIGN EXPECTED IN FIRST HALF
OF 2024
    * PROCESSA - ANALYSIS OF EXISTING PRE-CLINICAL DATA IN
ANIMALS TO
DEVELOP DRUG DEVELOPMENT ROADMAP FOR NGC-IRINOTECAN SEEN TO BE
COMPLETED IN EARLY 2024
    * PROCESSA PHARMACEUTICALS INC: AT SEP 30, HAD $6.9 MILLION
IN
CASH, BELIEVE IS SUFFICIENT TO COMPLETE OUR CURRENT PHASE 1B
STUDY FOR NGC-CAP
    * PROCESSA PHARMACEUTICALS INC: AT SEPT 30, HAD $6.9 MILLION
IN
CASH, BELIEVE IS SUFFICIENT TO FUND OUR CONTINUED OPERATIONS
INTO SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX6MX81V 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))